Open AccessMethotrexate-associated lymphoproliferative disorders in the central nervous system and stomach
Author(s) -
Mai Kawazoe,
Kaichi Kaneko,
Toshihiro Nanki
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000019850
Subject(s) - medicine , methotrexate , rheumatoid arthritis , gastroenterology , lymphoma , stomach , rituximab , central nervous system , chemotherapy , lymphoproliferative disorders
Rationale: Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is a serious complication in patients treated using methotrexate. It occasionally develops in extra-nodal sites, but rarely in the central nervous system (CNS) or in 2 different sites at the same time. We present the rare case of a patient with rheumatoid arthritis who developed lymphoma in the CNS and stomach during MTX therapy. Patient concerns: A 75-year-old Japanese man with rheumatoid arthritis who received methotrexate was admitted to our hospital because of gait ataxia and anorexia. Diagnoses: Imaging findings and biopsy led to a diagnosis of 2 different types of MTX-LPD in the central nervous system and stomach. Interventions: The lesion in his stomach improved after methotrexate withdrawal, whereas the cerebellar mass required high-dose methotrexate and rituximab therapy. Outcomes: Complete remission has been maintained for the 2 years following the initiation of chemotherapy. Lessons: In patients with RA who receive MTX and develop new neurological symptoms, CNS lymphoma as an MTX-LPD may be considered as a differential diagnosis.